RNAi technology and lentiviral delivery as a powerful tool to suppress Tpr-Met-mediated tumorigenesis

Cancer Gene Therapy

Volumn 12, Issue 5, 2005, Pages 456-463

  Taulli, Riccardo ^a,b   Accornero, Paolo ^a,b   Follenzi, Antonia ^b,c   Mangano, Tony ^a,b   Morotti, Alessandro ^a,b   Scuoppo, Claudio ^a,b   Forni, Paolo E ^a,b   Bersani, Francesca ^a,b   Crepaldi, Tiziana ^a,b   Chiarle, Roberto ^a   Naldini, Luigi ^b,d   Ponzetto, Carola ^a,b  

^a MOLINETTE HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Gastric cancer; Lentiviral vector; Novel cancer therapies; ShRNA; Tpr Met

Indexed keywords

LENTIVIRUS VECTOR; SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CANCER SUSCEPTIBILITY; CANCER THERAPY; CELL TRANSFORMATION; CHROMOSOME REARRANGEMENT; CONTROLLED STUDY; EMBRYO; EPITHELIUM CELL; FIBROBLAST; GENE ACTIVATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE; POINT MUTATION; PRECANCER; PRIORITY JOURNAL; RNA INTERFERENCE; STOMACH CANCER; STOMACH CARCINOGENESIS; STOMACH TUMOR; TPR MET GENE; VIRAL GENE DELIVERY SYSTEM;

EID: 20944448996     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700815     Document Type: Article

References (43)

1. Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391:806-811.
2. Kennerdell JR, Carthew RW. Use of dsRNA-mediated genetic interference to demonstrate that frizzled and frizzled 2 act in the wingless pathway. Cell. 1998;905:1017-1026.
3. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002;296:550-553.
4. Lee NS, Dohjima T, Bauer G, et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol. 2002;20:500-505.
5. Miyagishi M, Taira K. Development and application of siRNA expression vector. Nucleic Acids Res. 2002;2(Suppl):113-114.
6. Paddison PJ, Caudy AA, Bernstein E, et al. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev. 2002;16:948-958.
7. Kawasaki H, Taira K. Short hairpin type of dsRNAs that are controlled by tRNA(Val) promoter significantly induce RNAi-mediated gene silencing in the cytoplasm of human cells. Nucleic Acids Res. 2003;31:700-707.
8. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell. 2002;2:243-247.
9. Barton GM, Medzhitov R. Retroviral delivery of small interfering RNA into primary cells. Proc Natl Acad Sci USA. 2002;99:14943-14945.
10. Qin XF, An DS, Chen IS, et al. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA. 2003;100:183-188.
11. Rubinson DA, Dillon CP, Kwiatkowski AV, et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet. 2003;33:401-406.
12. van de Wetering M, Oving I, Muncan V, et al. Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector. EMBO Rep. 2003;4:609-615.
13. Czauderna F, Santel A, Hinz M, et al. Inducible shRNA expression for application in a prostate cancer mouse model. Nucleic Acids Res. 2003;31:e127.
14. Chen Y, Stamatoyannopoulos G, Song CZ. Down-regulation of CXCR4 by inducible small interfering RNA inhibits breast cancer cell invasion in vitro. Cancer Res. 2003;63:4801-4804.
15. Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4:915-925.
16. Tempest PR, Reeves BR, Spurr NK, et al. Activation of the met oncogene in the human MNNG-HOS cell line involves a chromosomal rearrangement. Carcinogenesis. 1986;7: 2051-2057.
17. Rodrigues GA, Park M. Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase. Mol Cell Biol. 1993;13:6711-6722.
18. Sharashidze LK, Beniashvili DSh, Sherenesheva NI, et al. Induction of gastric cancer in monkeys by N-methyl-N-nitro-N-nitrosoguanidine (MNNG). Neoplasma. 1989;36: 129-133.
19. Soman NR, Correa P, Ruiz BA, et al. The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions. Proc Natl Acad Sci USA. 1991;88:4892-4896.
20. Yu J, Miehlke S, Ebert MP, et al. Frequency of TPR-MET rearrangement in patients with gastric carcinoma and in first-degree relatives. Cancer. 2000;88:1801-1806.
21. Deng D, Xin H. Formation of N-(nitrosomethyl)urea in stomachs of experimental pigs and human volunteers given fish sauce in vivo. J Agric Food Chem. 2000;48:2495-2498.
22. Sen NP, Seaman SW, Badoo PA, et al. Formation of N-nitroso-N-methylurea in various samples of smoked/dried fish, fish sauce, seafoods, and ethnic fermented/pickled vegetables following incubation with nitrite under acidic conditions. J Agric Food Chem. 2001;49:2096-2103.
23. Danilkovitch-Miagkova A, Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest. 2002;109:863-867.
24. Lee JH, Han SU, Cho H, et al. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene. 2000;19:4947-4953.
25. Ma PC, Kijima T, Maulik G. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 2003;63:6272-6281.
26. Shinomiya N, Vande Woude GF. Suppression of met expression: a possible cancer treatment. Clin Cancer Res. 2003;9:5085-5090.
27. Ma PC, Maulik G, Christensen J, et al. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metast Rev. 2003;22:309-325.
28. Morotti A, Mila S, Accornero P, et al. K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene. 2002;21:4885-4893.
29. Sattler M, Pride YB, Ma P, et al. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res. 2003;63:5462-5469.
30. Christensen JG, Schreck R, Burrows J, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. 2003;63: 7345-7355.
31. Maritano D, Accornero P, Bonifaci N, et al. Two mutations affecting conserved residues in the Met receptor operate via different mechanisms. Oncogene. 2000; 19:1354-1361.
32. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411:494-498.
33. Follenzi A, Ailles LE, Bakovic S, et al. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet. 2000;25: 217-222.
34. Weidner KM, Arakaki N, Hartmann G, et al. Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc Natl Acad Sci USA. 1991;88: 7001-7005.
35. Goldman JM, Melo JV. Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med. 2003;349:1451-1464.
36. Croom KF, Perry CM. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs. 2003;63: 513-522.
37. Bose S, Deininger M, Gora-Tybor J, et al. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood. 1998;92:3362-3367.
38. Yang G, Thompson JA, Fang B, et al. Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumor growth in a model of human ovarian cancer. Oncogene. 2003;22:5694-5701.
39. Scherr M, Battmer K, Winkler T, et al. Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood. 2003;101:1566-1569.
40. Hingorani SR, Jacobetz MA, Robertson GP, et al. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 2003;63:5198-5202.
41. Li K, Lin SY, Brunicardi FC, Seu P. Use of RNA interference to target cyclin E-overexpressing hepatocellular carcinoma. Cancer Res. 2003;63:3593-3597.
42. Filleur S, Courtin A, Ait-Si-Ali S, et al. SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res. 2003;63:2319-2322.
43. Weinstein IB. Cancer, addiction to oncogenes - the Achilles heal of cancer. Science. 2002;297:63-64.